Plus Therapeutics (PSTV) said Friday that its experimental drug, rhenium obisbemeda, demonstrated a median overall survival of 11 months in an early-stage study, outperforming the standard of care of 8 months for recurrent glioblastoma, a type of brain tumor.
The clinical-stage company said that the study showed no dose-limiting toxicity, and that the majority of adverse events were unrelated to the treatment.
Plus Therapeutics said that, based on these results, it is currently enrolling patients in a mid-stage trial at medical centers.
Shares of the company climbed as much as 40% in recent premarket activity on Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。